Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Disorders of bone and mineral metabolism are common in patients with chronic kidney disease (CKD). Elevated serum phosphorus contributes to bone disease, vascular calcification, and higher mortality, so any strategy aimed at lowering it is desirable. Hyperkalemia is also frequent in CKD, particularly in hemodialysis (HD) patients, and is associated with increased morbidity and mortality. Patiromer, a recently introduced potassium binder, may also influence mineral metabolism due to its calcium content.
We conducted a multicenter, prospective, real-world study to assess the effect of patiromer on biochemical parameters of bone and mineral metabolism, particularly serum phosphorus, in CKD stages 3–5. Patiromer was prescribed for chronic hyperkalemia. Epidemiological and clinical data were collected, and serum potassium, calcium, magnesium, and phosphorus levels were analyzed over time.
Fifty-two patients (mean age 71±12 years; 75% male; 63% diabetic; 54% with heart failure; 48% on phosphate binders) were included. Regarding CKD stage, 17% were in stage 3b, 31% in stage 4, 38% in stage 5 (non-dialysis), and 13% on HD. Forty-six patients completed six months of follow-up; two died, two received a kidney transplant, and two were transferred. All patients started patiromer at 8.4 g once daily; only one required dose doubling. Patiromer use led to a 27% reduction in serum potassium (5.9 to 4.6 mEq/L; P<0.001). No significant changes were observed in serum calcium or magnesium. Serum phosphorus decreased by 18% (5.1 to 4.2 mg/dL; P=0.022), without changes in diet or phosphate binder therapy. The decrease in phosphate correlated with baseline phosphate levels (r=0.367; P=0.039). Patiromer was well tolerated; only two patients reported mild constipation, and no treatment discontinuations occurred.
Patiromer is effective and well tolerated for reducing serum potassium in CKD. Its calcium content may also lower serum phosphorus by reducing intestinal phosphorus absorption, similar to calcium-based phosphate binders. Patiromer might therefore have a dual role in CKD management—addressing both hyperkalemia and hyperphosphatemia.
